Bone Marrow Stem Cells in Cardiac Repair. 2 Dimmeler S et al. Arterioscler Thromb Vasc Biol. 2007;Oct. 19 epub. EC differentiation SMC differentiation.

Slides:



Advertisements
Similar presentations
Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis Heart Institute at Abbott Northwestern Hospital University of Minnesota Medical School.
Advertisements

Kai Pinkernell, MD 4 th Int. Symp. Stem Cell Therapy & CV Biology Madrid, Spain 26 th of April 2007 Adipose Derived Stem Cell Therapy in Cardiovascular.
Department of Cardiovascular Medicine John Radcliffe Hospital, Oxford
Understanding the Mechanisms and the Potential of Cell Therapy for the Repair of the Adult Mammalian Heart Keng Ang VII International Symposium on Stem.
Intracoronary Autologous Bone-Marrow Cell Transfer after Myocardial Infarction: A Double-Blind, Randomized, and Placebo-Controlled Clinical Trial Presented.
prognosis of patients with Acute Myocardial Infarction remains dismal.
M. Valgimigli University of Ferrara Italy Autologous bone marrow stem cell mobilization Induced by G-CSF after MI Autologous bone marrow stem cell mobilization.
Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis Heart Institute at Abbott Northwestern Hospital University of Minnesota Medical School.
Cyclosporine A reduces infarct size and has no detrimental effect of LV remodeling in STEMI patients Michel Ovize Cardiology Hospital and Inserm U886 Lyon.
Stem Cell Implants to Repair Damaged Hearts Rationale Two clinical trials – Cardiac-derived stem cells Cedars Sinai Medical Center, Dr. Eduardo Marban.
{ R. Diaz-Garcia MD, J. Bernardo MD Stem Cell Therapy for Patients with Critical Limb Ischemia: A Meta-analysis with Critical Limb Ischemia: A Meta-analysis.
Stem cell therapy in cardiac practice
Heartline Trial sulla terapia cellulare:
Department of Internal Medicine – VCU Grand Rounds November 20, 2008 Cardiac remodeling following acute myocardial infarction Antonio Abbate, MD Assistant.
Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.
Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis Heart Institute at Abbott Northwestern Hospital University of Minnesota Medical School.
Endothelial Progenitor Cells (EPCs)
Ongoing Trials in Managing Myocardial Ischemia. MERLIN-TIMI 36: Study design IV/oral ranolazinePlacebo Patients with non-ST elevation ACS treated with.
From Bench to Bedside Step 1:First-time application of DESWT in a rodent model of ischemic HF (pilot trial); redesign of device Step 2:In-vitro validation.
Safety and effectiveness of granulocyte-colony stimulating factor in advanced chronic heart failure Jacob Joseph, MD Veterans Affairs Healthcare System-
Jay H Traverse, MD Principal Investigator, LateTIME Study Minneapolis Heart Institute at Abbott Northwestern Hospital University of Minnesota Medical School.
Regeneration and stem cells Definition 1) Self-renewing capability  Clonal expansion 2) Differentiation into various types of cells, multipotent = self.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Relationship Between Vascular Endothelial Growth.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Sonic Hedgehog-Induced Functional Recovery After.
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: 17-Beta-Estradiol increases cardiac remodeling and.
IN THE NAME OF GOD. What are Stem Cells? Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiopoietic Stem Cell Therapy in Heart Failure:
Skeletal Myoblast Cells. 2 Skeletal myoblasts Derived from satellite cells in skeletal muscle With appropriate stimulus, satellite cells differentiate.
Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Stem Cell Mobilization by Granulocyte Colony-Stimulating.
Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Intracoronary Cardiosphere-Derived Cells After Myocardial.
Date of download: 9/20/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Aging on Human Mesenchymal Stem Cell Therapy.
Date of download: 11/11/2016 Copyright © The American College of Cardiology. All rights reserved. From: Targeted Left Ventricular Lead Placement to Guide.
By Justin Klee and Lucy Schultz
The TIME Randomized Trial:
Cell Repair Therapy – Phase 1 Lessons Learned – Clinical Studies
The NHLBI TIME Trial: Role of Microvascular Obstruction in 2-Year Clinical and MRI Follow-up Jay H. Traverse, MD Principal Investigator, TIME Study Minneapolis.
Tauroursodeocycholic acid, bile acid, induces blood vessel repair
Paracrine Action Enhances the Effects of Autologous Mesenchymal Stem Cell Transplantation on Vascular Regeneration in Rat Model of Myocardial Infarction 
Intravenously Delivered Mesenchymal Stem Cells:
Epicardial injection of Ad-HGF activates endogenous
Arterioscler Thromb Vasc Biol
Arterioscler Thromb Vasc Biol
Cell Therapy 2014 Las Vegas, NV, USA
Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis 
Cell therapy with autologous bone marrow mononuclear stem cells is associated with superior cardiac recovery compared with use of nonmodified mesenchymal.
TECAM Trial design: STEMI patients who underwent successful reperfusion therapy were randomized on day 1 to intracoronary bone marrow autologous mononuclear.
Materials Science and Tissue Engineering: Repairing the Heart
by Alexis S. Bailey, Shuguang Jiang, Michael Afentoulis, Christina I
Volume 8, Issue 4, Pages (April 2011)
Cardiac Cell Repair Therapy: A Clinical Perspective
Downregulation of the CXC chemokine receptor 4/stromal cell–derived factor 1 pathway enhances myocardial neovascularization, cardiomyocyte survival, and.
Paracrine Action Enhances the Effects of Autologous Mesenchymal Stem Cell Transplantation on Vascular Regeneration in Rat Model of Myocardial Infarction 
POSEIDON-DCM Trial design: Patients with nonischemic dilated cardiomyopathy were randomized to transendocardial injection of allogenic (n = 18) vs. autologous.
Edaravone promotes activation of resident cardiac stem cells by transplanted mesenchymal stem cells in a rat myocardial infarction model  Guang-Wei Zhang,
Cell transplantation preserves cardiac function after infarction by infarct stabilization: Augmentation by stem cell factor  Shafie Fazel, MD, MSc, Liwen.
Volume 5, Issue 5, Pages (November 2015)
A novel vascularized patch enhances cell survival and modifies ventricular remodeling in a rat myocardial infarction model  Qi Zhou, MD, PhD, Jian-Ye.
Homing of intravenously infused embryonic stem cell-derived cells to injured hearts after myocardial infarction  Jiang-Yong Min, MD, Xuling Huang, MD,
Volume 23, Issue 2, Pages (June 2016)
Mesenchymal, but not hematopoietic, stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction in mice  Keiichi Fukuda,
Randomized Study of Mononuclear Bone Marrow Cell Transplantation in Patients With Coronary Surgery  Qiang Zhao, MD, Yongxin Sun, MD, Limin Xia, MD, Anqing.
EMERGING ROLE OF STEM CELLS In CARDIOVASCULAR THERAPY
Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation  Shinji Tomita, MD, PhD, Donald.
Volume 114, Issue 6, Pages (September 2003)
Volume 12, Issue 6, Pages (December 2005)
Significant improvement of heart function by cotransplantation of human mesenchymal stem cells and fetal cardiomyocytes in postinfarcted pigs  Jiang-Yong.
Eduardo Marbán, MD, PhD  Mayo Clinic Proceedings 
A Repair “Kit” for the Infarcted Heart
Xenotransplant cardiac chimera: immune tolerance of adult stem cells
Volume 26, Issue 7, Pages (July 2018)
Presentation transcript:

Bone Marrow Stem Cells in Cardiac Repair

2 Dimmeler S et al. Arterioscler Thromb Vasc Biol. 2007;Oct. 19 epub. EC differentiation SMC differentiation Paracrine Effects Cardiac differentiation fusion Angiogenesis Attraction/ Activation of CSC Arteriogenesis Cardiomyocyte proliferation  Cardiomyocyte apoptosis Scar remodeling Modulation of inflammation FUNCTIONAL IMPROVEMENT Vasculo- genesis Cardio- myogenesis Cell homing and tissue integration Stem cells in cardiac repair: Proposed mechanisms of action

3 Bone marrow cells promote myocardial regeneration: Postulated mechanism Orlic D et al. Nature. 2001;410: Transplanted Cells Infarcted myocardium Cell migration to damaged area Proliferation and differentiation Cytoplasmic proteinsNuclear proteins Functional competence Unknown molecular signal(s) Cardian myosin α-Sarcomeric actin Connexin 43 Csx/Nkx2.5 MEF2 GATA-4

4 Deb A et al. Circulation. 2003;107: Blue, green arrow = Y chromosome–positive true nucleus of BM Red = Derived cardiomyocyte cytoplasm (sarcomeric actin) surrounded by basement membrane laminin (green, arrowhead) Post-mortem analysis of 4 hearts of female recipients of male BM transplants Demonstration of Y-chromosomes in up to 23% of cardiomyocytes Cardiac stem cells are derived, in part, from bone marrow

5 Communication between heart and bone marrow signals in repair Courtesy of Carl J. Pepine, MD SDF-1 SDF-1 transport CXCR4 Cell Recruitment Stem/progenitor cell Maturing leukocyte Heart Blood vessel endothelium Bone Bone marrow endosteum Blood vessel endothelium

6 Orlic D et al. Nature. 2001;410: mm Hg * * † LVEDP mm Hg * * † LVDP mm Hg s * * † LV +dP/dt * * † LV –dP/dt mm Hg s SOMI + BMMISOMI + BMMI Ventricular function BMCs regenerate infarcted myocardium in mice

7 Kamihata H et al. Circulation. 2001;104: BMCs reduce perfusion defect in ischemic pig hearts

8 Kamihata H et al. Circulation. 2001;104: LAD LigationBM-MNC after 3 weeks BMCs enhance collaterals to infarct region

9 BMC therapy increases angiogenesis in ischemic pig hearts In part via enhanced synthesis of angiogenic factors in the infarcted region (ie, VEGF) Kamihata H et al. Circulation. 2001;104: BM-MNC (Factor-VII) Control Medium (Factor-VIII)

10 Infarcted myocardium repair via autologous intracoronary mononuclear BMC transplantation Strauer BE, et al. Circulation. 2002;106: Human model

11 BMCs minimize infarcted myocardium region At 3 months: SV index 49  56, P = 0.01 Left ventricular end-systolic volume 82  67, P = 0.01 Thallium scintigraphy, cm  128 Strauer BE et al. Circulation. 2002;106: Cell therapyStandard therapy Infarct region (%) * P = 0.04

12 Assessment of intracoronary cell therapy in AMI StudyDesign N enrolled (follow-up)Cell type Follow-up (months)Primary endpoint Strauer, 2002Non-RCT20(20)BMC3LVEF Bartunek, 2005Non-RCT35 (35)BMC4Safety, LVEF Jannsens, 2006RCT67 (66)BMC4LVEF BOOST, 2006RCT60 (60)BMC18LVEF, safety Zhan-Quang, 2006Non-RCT70 (58)PMC6LVEF, LV vol, WMSI MAGIC CELL-3- DES, 2006 RCT56 (50)PMC6LVEF TCT-STAMI, 2006RCT20 (20)BMC6LVEF ASTAMI, 2006RCT100 (97)BMC6LVEF, EDV, infarct size REPAIR-AMI, 2006RCT204 (197)BMC12LVEF Meluzin, 2006RCT66 (66)BMC3Infarct zone systolic function Lipinsky MJ et al. J Am Coll Cardiol. 2007;50: PMC = peripheral mononuclear cells; RCT= randomized controlled trial; WMSI = wall motion score index.

13 Effects of intracoronary cell therapy on LVEF Lipinsky MJ et al. J Am Coll Cardiol. 2007;50: Test for heterogenicity, Chi 2 = 33.62,  f = 9 (P = ), P = 73.2% Test for overall effect: Z = 5.35 (P = ) StudyEF change % (random)EF change % or sub-category95% CI95% CI ASTAMI, (-2.81, 0.01) Bartunek, (-9.14, 2.94) BOOST, (-3.00, -0.60) Jannsens, (-2.68, 0.68) MAGIC-3, (-7.18, 1.23) Meluzin, (-2.94, -1.04) REPAIR-AM, (-1.54, -1.44) Strauer, (-4.06, 2.04) TCT-STAMI, (-1.89, -3.51) Zhan-Quan, (-3.19, -2.83) Total-2.97 (-1.04, -1.22) Favors cell therapyFavors control

14 Autologous CD34 + cells for intractable angina N = 24 patients with CCS class 3/4 angina G-CSF 5 μg/kg/day x 5 days Leukapheresis performed on Day 5 CD34 + cell selection NOGA-guided transplantation to zones of myocardial ischemia Phase I/IIa double-blind, 3:1 randomization, with crossover of placebo patients using frozen cells Losordo DW et al. Circulation. 2007;115:

15 Decrease in angina frequency with CD34 + cell therapy Months Losordo DW et al. Circulation. 2007;115: